论文部分内容阅读
目的探讨替吉奥联合奥沙利铂治疗晚期胃癌的临床治疗效果。方法本院2010年3月～2011年3月间共收治的晚期胃癌患者29例。所有患者均接受化疗,采用替吉奥胶囊80mg/(m2d),早晚餐后口服,第1～14天;第1天联合奥沙利铂130mg/m2(行静脉滴注3h);停药7天,每21天重复l次为一个周期,最少治疗两个周期。结束治疗后对患者治疗效果及不良毒副反应进行评价分析。结果所有患者总有效率为58.6%,完全缓解2例,部分缓解15例,病情稳定7例,病情进展5例。患者平均生存时间为10个月。其不良毒副反应表现为骨髓抑制,神经毒性及胃肠道反应。结论对晚期胃癌患者采用替吉奥联合奥沙利铂进行治疗,能有效提高临床治疗效果,且此方法安全有效,值得临床推广。
Objective To investigate the clinical efficacy of tegafur combined with oxaliplatin in the treatment of advanced gastric cancer. Methods Twenty-nine patients with advanced gastric cancer were treated in our hospital between March 2010 and March 2011. All patients received chemotherapy, using 80 mg/(m2d) of teigio capsules, oral administration after breakfast and dinner for 1 to 14 days, and oxaliplatin 130 mg/m2 (intravenous infusion of 3 h) on the first day; Days are repeated once every 21 days for one cycle and at least two cycles for treatment. After the end of treatment, the patient’s treatment effect and adverse toxicities were evaluated and analyzed. Results The total effective rate of all patients was 58.6%, 2 cases were complete remission, 15 cases were partial remission, 7 cases were stable, and 5 cases progressed. The average survival time of patients was 10 months. The adverse toxicities were manifested as myelosuppression, neurotoxicity and gastrointestinal reactions. [Conclusion] The treatment of advanced gastric cancer patients with tegrio combined with oxaliplatin can effectively improve the clinical treatment effect. This method is safe and effective, and worthy of clinical promotion.